乳腺癌分子分型的临床病理表现

Clinical Pathological Features of Breast Cancer of Different Molecular Subtypes

目的 探讨乳腺癌各分子分型的临床病理表现.方法 回顾性分析2009年1～12月首都医科大学附属北京朝阳医院收治的79例乳腺癌患者的年龄、病理类型、肿瘤大小、腋窝淋巴结转移情况、免疫组织化学结果等临床资料.结果 79例浸润性乳腺癌中,年龄为36～ 87岁,中位年龄53岁.病理类型以浸润性导管癌为主,占83.5％.其中,Luminal A型38例（48.1％）,Luminal B型23例（29.1％）,人类表皮生长因子受体2（HER-2）过表达型3例（3.8％）,基底细胞样型15例（19.0％）.乳腺癌分子分型与肿瘤大小及美国癌症联合委员会分期的差异有统计学意义（P＜0.05）,而与年龄、腋窝淋巴结转移数、病理组织分级差异无统计学意义（P＞0.05）.预后以Luminal A型及基底细胞样型最好,Luminal B型其次,HER-2过表达型最差.结论 乳腺癌分子分型对临床治疗及预后的评估非常重要,与传统临床病理指标结合可为临床工作提供重要依据.

Objective To investigate the clinical and pathological features of breast cancer of different molecular subtypes.Methods Retrospective analysis of age,pathological type,tumor size,lymph node metastasis,immunohistochemishT results and other clinical information of 79 cases of breast cancer admitted to Chaoyang Hospital of Capital Medical University in Jan.-Dec.2009 was done.Results Among the 79cases of invasive breast cancer,aged from 36-87 years,with the median age of 53 years old.There were 66cases（83.5%） of invasive ductal carcinoma among the 79 cases,including luminal A type 38 cases （48.1%）,luminal B type 23 cases （29.1%）,HER-2 overexpression type 3 cases（3.8 %）,basal-like type 15 cases（19.0%）.Statistical analysis showed that the difierences of molecular subtype of breast cancer,tumor size and the AJCC staging were statistically significant P 〈 0.05）,while age,number of axillary lymph node metastasis,histopathologic grading had no statistically significant difference（P 〉 0.05）.Prognosis in luminal A type and basal-like type were the best,luminal B was second,and HER-2 overexpression type was the worst.Conclusion Breast cancer molecular classification is very important for clinical treatment and prognosis evaluation,which can provide important basis for clinical work combined with traditional clinical pathological indicators.